Chris Linthwaite

“In the third quarter, we executed on our three-part strategy to leverage the power of our core technologies. We saw a very active third quarter and made progress on our ambitious plan to commercially scale two new instrument systems.”

“In the second quarter, our base business top-line revenue continued to rebound from 2020 levels with notable growth in mass cytometry services and non-COVID related microfluidics products.”

“In the first quarter, we delivered on our financial projections and made incremental progress on our Vision 2025 objectives. Amazingly, this last quarter marked the 1-year anniversary of the global pandemic.”

“As I think about everything that's happened in the past year, it's clear that the ongoing global pandemic has affected every aspect of our business, driving the need for seamless execution as well as opening new doors and accelerating greater opportunities.”

“The ongoing global pandemic has impacted every facet of our business and has driven a need for speed as well as crisp execution. Our disciplined operations, our relentless focus on employee safety, addressing urgent COVID market needs through innovation, and a focused capital deployment plan has delivered results.”